Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer
All-Comers Approach Disappoints
Executive Summary
Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.
You may also be interested in...
Third Time Is Not A Charm: KEYLYNK-006 Is Latest Keytruda/Lynparza Study To Fail
Merck said the Phase III study of the combination in non-small cell lung cancer did not meet its dual primary endpoint of overall survival and progression-free survival.
Merck Reports Good News/Bad News In Latest Keytruda Readouts
With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.
Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.